Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Accumulated Depreciation (2019 - 2025)

Revolution Medicines (RVMD) has 7 years of Accumulated Depreciation data on record, last reported at $28.5 million in Q4 2025.

  • For Q4 2025, Accumulated Depreciation rose 30.66% year-over-year to $28.5 million; the TTM value through Dec 2025 reached $28.5 million, up 30.66%, while the annual FY2025 figure was $28.5 million, 30.66% up from the prior year.
  • Accumulated Depreciation reached $28.5 million in Q4 2025 per RVMD's latest filing, up from $27.0 million in the prior quarter.
  • Across five years, Accumulated Depreciation topped out at $28.5 million in Q4 2025 and bottomed at $9.5 million in Q2 2021.
  • Average Accumulated Depreciation over 5 years is $17.9 million, with a median of $17.3 million recorded in 2023.
  • Peak YoY movement for Accumulated Depreciation: skyrocketed 39.49% in 2021, then increased 20.48% in 2024.
  • A 5-year view of Accumulated Depreciation shows it stood at $10.8 million in 2021, then skyrocketed by 34.01% to $14.5 million in 2022, then grew by 22.12% to $17.7 million in 2023, then increased by 23.34% to $21.8 million in 2024, then soared by 30.66% to $28.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Depreciation were $28.5 million in Q4 2025, $27.0 million in Q3 2025, and $23.4 million in Q1 2025.